<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

1 min read

2022 Outlook for US Breast Matrices: Recent Trends and Future Impact

3/15/22 8:00 AM

2022 Outlook for US  Breast Matrices V3 copySmartTRAK examines recent trends in breast implants and discusses their future impact on breast matrices.

Breast matrices, whether acellular dermal matrices (ADMs) or biosynthetics, have enabled improved outcomes in implant-based breast reconstruction and have contributed, in large part, to the revival of the prepectoral breast reconstruction technique. As the number of breast implant procedures has grown, so has the use of breast matrices. However, SmartTRAK believes the side effects and health consequences now associated with breast implants, while rare, will negatively impact breast implant usage and thus reduce the growth rate of breast matrices in 2022 and beyond.

In this informative Outlook article by Doug Devens, SmartTRAK's Product Director and Senior Editor, Wound, Doug covers:

  • The Relationship between Breast Surgery and ADM Usage
  • Trends in Implant Usage
  • Recent Concerns that May Affect Breast Implant Usage
  • The Future Outlook for 2022 and Beyond

Breast reconstructions will continue to increase with demographic trends as will the absolute number of implant procedures, as they are still an important tool in breast reconstruction. However, the growth rate of implant procedures faces headwinds. The public appears to be taking closer note of FDA warnings associated with ...

To read the complete SmartTRAK article "2022 Outlook for Breast Matrices" by Doug Devens, please click the button below.

Download the 2022 Outlook for Breast Matrices Article


SmartTRAK now offers Skin Substitutes (CTP) Site of Care. This module will make you an expert in Site of Care information for the Skin Substitutes market and includes market shares, 5-Year Growth Projections and Company & Product Performance across multiple sites of care. Download our PDF to get a preview of what's available!

 

Doug Devens
Written by Doug Devens

20 years of diverse medical device experience, including leading companies 3M, Coloplast and Boston Scientific, along with emerging companies. Leadership experience in product development, including championing the process for voice of customer and concept feedback sessions with key thought leaders.

    Follow Us on Social Media

    Recent Articles